Meridian Bioscience Inc

Meridian Bioscience — Merger or Acquisition (July 2022)

11 slides from Meridian Bioscience's merger presentation, Jul 7, 2022

  1. Slide 1: Town Hall presentation July 2022

    Town Hall presentation July 2022

  2. Slide 2: SD Biosensor / SJL Partners to buy Meridian

    SD Biosensor / SJL Partners to buy Meridian Overview Buying consortium Entered a definitive merger agreement whereby we will be acquired for approximately $1.5 billion paid in all cash Meridian stockholders will receive $34.00 per share This deal will end our standing as a publicly-held company trad

  3. Slide 3: Who is SD Biosensor?

    SD Biosensor is a South Korean based global leader in diagnostics Has great expertise in new product development and in driving scale and quality from an operations standpoint Scaled from <$100 million in revenue pre-pandemic to $4 billion at the peak of the pandemic Has several new products that wi

  4. Slide 4: Who is SJL Partners?

    SJL Partners is a South Korean private equity fund that focuses on cross-border opportunities Combined approach drives value in a deal with a “best of both worlds” strategy Combination of SJL’s backing and experience with a strategic buyer drives synergies while minimizing risk SJL has long promoted

  5. Slide 5: Why are we excited about this transaction?

    Acceleration of the transformation of Meridian 2.0 into Meridian 3.0 Commitment by combined management to drive the next 5-year strategy plan Continuation of current structure with no anticipated employment or structural changes Attractive value for stockholders while strengthening Meridian’s positi

  6. Slide 6: What does this mean for employees?

    This transaction will create a more competitive company better positioned for growth with more enhanced opportunities. Meridian is expected to increase headcount as the business continues to grow. One of the things that attracted SD Biosensor and SJL to us is the strength of our talented employees a

  7. Slide 7: Partnership drives mutual benefits

    Partnership drives mutual benefits Expertise in new product development and driving scale and quality in operations Several new products will enhance offerings for the Diagnostics business (from the SDB business) and for the Life Science business (from the BioNote business) BioNote to expand sales i

  8. Slide 8: SD Biosensor and SJL Partners' goals

    SD Biosensor and SJL Partners’ goals Unlock sales synergies between the Diagnostics business and SD Biosensor and the Life Science business and BioNote Diagnostics business has a strong presence in the U.S., the influx of new products will enable Meridian to accelerate growth Life Science business w

  9. Slide 9: What do we need to do?

    What do we need to do? It is paramount everyone remains focused continuing to deliver great products and best-in-class service to our customers around the world. Please note that the CIP bonus plan will be distributed as planned in December Commitment Meridian’s future is bright, and under new owner

  10. Slide 10: Future opportunities

    Future opportunities Meridian 2.0 Jack Kenny appointed as CEO Integrated businesses into two divisions: Life Science & Diagnostics Implemented strategic planning initiatives Diagnostics product portfolio investment (Immunoassay analyzer, menu expansion, acquisitions) Life Science operational pivot (

  11. Slide 11: Additional Information and Where to Find It

    Q&A Additional Information and Where to Find It In connection with the proposed transaction, the Company intends to file relevant information with the SEC, including a proxy statement on Schedule 14A. This communication is not a substitute for the Proxy Statement or for any other document that the C

Meridian Bioscience — Merger or Acquisition (July 2022) on 6ix